Convelo Therapeutics, Inc. has entered into an exclusive worldwide collaboration with Genentech to accelerate discovery and development of novel remyelinating medicines for neurological disorders such as multiple sclerosis (MS).     Convelo will receive an undisclosed upfront payment and research support from Genentech. Genentech will retain an exclusive option to acquire all outstanding stock of Convelo for an additional undisclosed payment and downstream milestones.    “We are excited to b...